18:00 EDT Pliant Therapeutics (PLRX) files $300M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics price target lowered to $3 from $4 at Canaccord
- How Shareholder Activism Could Disrupt Pliant Therapeutics’ Strategy, Costs, and Stock Performance
- Pliant Therapeutics price target lowered to $3 from $4 at Piper Sandler
- Pliant Therapeutics reports Q4 EPS (38c), consensus (38c)
- Pliant Therapeutics Extends Stockholder Rights Agreement Expiration